Injectable Drugs Market Size, Share, Growth and Forecast, 2025-2035

Biologics and peptides drive parenteral medicine spending

The global injectable drugs market was valued at USD 620.86 billion in 2025 and is projected to increase from USD 660.04 billion in 2026 to USD 1,144.90 billion by 2035, registering a CAGR of 6.31% during 2026–2035. Demand comes from monoclonal antibodies in cancer and immunology, fast growth in peptide hormones for diabetes and obesity, and steady hospital use of anti-infective and anesthetic products. North America held the largest regional share, 45.0% in 2025, because branded biologics carry high prices and broad insurance coverage. Asia Pacific is the fastest-growing region at 7.62% a year, as China, India and Southeast Asia widen access to biologic therapy and local manufacturing. The delivery picture changed in September 2025, when the FDA approved a subcutaneous form of a leading cancer immunotherapy that previously required intravenous infusion. As a result, originators are moving more infused medicines to shorter injections.

Which parenteral medicines and channels does this analysis cover?

The analysis counts prescription medicines given by intravenous, subcutaneous, intramuscular and other parenteral routes, including monoclonal antibodies, peptide hormones, insulin, anti-infectives, cytokines, immunoglobulins, blood factors and anesthetics, valued at manufacturer selling prices. Hospitals buy most infused and acute-care products, while patients fill self-administered pens and syringes through retail and online pharmacies.

Empty delivery devices, contract manufacturing fees, vaccines given as public health programs and medical devices without a medicine sit outside the scope of this analysis. The value chain runs from active ingredient and biologic producers through sterile fill-finish sites to wholesalers, specialty distributors, pharmacies and payers, which set formulary access and patient costs.

Monoclonal antibodies lead as peptide hormones gain fastest

Why do monoclonal antibodies lead parenteral spending?

Based on therapeutic area, the market is categorized into anesthetics, anti-infective agents, blood factors, cytokines, immunoglobulins, insulin variants, monoclonal antibodies, peptide hormones and others. Monoclonal Antibodies led with a 38.0% share of 2025 value, because immunotherapy and autoimmune treatment rely on high-value antibody products. Peptide Hormones grow fastest at 7.83% a year, as weekly incretin therapies for diabetes and obesity reach millions of new patients each year.

How do large molecule biologics outpace small molecules?

Based on molecule type, the market is categorized into large molecule biologics and small molecule injectables. Large Molecule Biologics led with a 68.0% share of 2025 value and also grow fastest at 6.68% a year, because antibodies, peptides and enzymes cannot be taken orally. Small molecule products remain essential in hospitals for anesthesia, infection and emergency care. However, many of these products are generic and face steady price erosion.

Where do patients and hospitals obtain parenteral medicines?

Based on distribution channel, the market is categorized into hospital pharmacy, retail pharmacy, online pharmacy and others. Hospital Pharmacy led with a 52.0% share of 2025 value, because infusions, anesthetics and acute anti-infectives are given inside hospitals. Online Pharmacy grows fastest at 8.26% a year, as online pharmacy platforms deliver chilled pens and syringes to patients on chronic therapy.

Chronic disease and biologic pipelines lift demand

How do antibody pipelines sustain demand in cancer care?

Antibody pipelines sustain demand in cancer care, because checkpoint inhibitors and targeted antibodies are now standard in many tumor types. These medicines are given by infusion or injection, which keeps parenteral routes central to oncology spending. In September 2025, the FDA approved Keytruda Qlex for adults and pediatric patients aged 12 and older across the solid tumor indications of intravenous pembrolizumab. The label allows dosing every three weeks or every six weeks, which suits both community clinics and large cancer centers. As a result, cancer centers can treat more patients in shorter chair times through 2035.

Why do peptide hormones add the largest new patient groups?

Peptide hormones add the largest new patient groups, because incretin therapies for type 2 diabetes and obesity are given as weekly self-injections. Demand for these medicines has repeatedly outpaced supply since 2023, which pushed makers to expand sterile capacity. In February 2025, Eli Lilly and Co. announced four new U.S. manufacturing sites, with one site extending its capacity for injectable therapies. The plan adds about 3,000 permanent jobs and 10,000 construction jobs within five years. In turn, larger supply will let more patients start and stay on treatment.

Download Free Sample

How does a growing biologic approval stream widen choice?

A growing biologic approval stream widens treatment choice, because many new medicines are proteins that require parenteral delivery. The FDA Center for Drug Evaluation and Research approved 50 novel drugs in 2024, including many antibodies and peptides. The agency also approved a record 18 biosimilars for eight reference products in 2024, which brings lower-cost options into hospital and specialty channels. As a result, both innovation and competition expand the number of patients who receive injected therapy.

Why does long-acting prevention open new injected uses?

Long-acting prevention opens new injected uses, because twice-yearly or monthly doses remove the burden of daily pills. In June 2025, the FDA approved Gilead Sciences Inc. Yeztugo, a twice-yearly lenacapavir injection for HIV pre-exposure prophylaxis in adults and adolescents weighing at least 35 kilograms. This approval shows how long-acting formulations can reach healthy people at risk, not only patients with disease. In turn, prevention programs create recurring demand for clinic-given injections.

Subcutaneous forms and long-acting doses reshape care

How is the shift from infusion to subcutaneous injection reshaping care?

The shift from infusion to subcutaneous injection is reshaping care, because shorter administration frees infusion chairs and staff time. In September 2024, Roche announced FDA approval of Ocrevus Zunovo, a twice-yearly injection for relapsing and primary progressive multiple sclerosis that takes about 10 minutes. In the 236-patient OCARINA II trial, more than 92% of participants were satisfied or very satisfied with subcutaneous dosing. In December 2024, the FDA approved Opdivo Qvantig, a subcutaneous nivolumab from Bristol Myers Squibb Co. As a result, more antibody brands now launch with both intravenous and subcutaneous versions.

Why is self-administration rising for chronic therapy?

Self-administration is rising for chronic therapy, because patients with diabetes, obesity and autoimmune disease prefer treatment at home. Prefilled syringes reduce dosing errors and contamination risk compared with vial and syringe preparation by patients. This change moves more volume from hospital pharmacies to retail and online pharmacies over the forecast period. In turn, makers invest in patient training and support programs that keep people adherent between clinic visits.

Download Free Sample

Can biosimilar competition open wider access to biologics?

Biosimilar competition gives payers a clear opening to widen access, because lower prices allow more patients to start biologic therapy. The FDA approved 18 biosimilars in 2024, including nine interchangeable products that pharmacists may substitute under state rules. Those approvals brought the U.S. total to 60 biosimilars since the first approval in 2015. Biosimilar versions of antibodies for immunology and cancer are already reshaping hospital tenders. As a result, companies with efficient sterile manufacturing can win volume in price-sensitive markets.

Where can connected delivery devices add value?

Connected delivery devices give manufacturers room to add value, because missed or incorrect doses reduce the benefit of chronic therapy. Reusable autoinjectors and smart pens can record dose timing and share it with care teams through phone apps. This information helps clinicians adjust treatment before a patient loses disease control. In turn, companies that pair medicines with adherence data can support payer contracts based on outcomes.

Sterile capacity, cold chain and price pressure limit gains

Why does sterile manufacturing capacity limit supply?

Sterile manufacturing capacity limits supply, because fill-finish lines need aseptic controls, long validation and specialized staff. Shortages of incretin pens since 2023 showed how quickly demand can exceed available capacity for a new class. In December 2024, Novo Holdings completed its acquisition of Catalent, and three fill-finish sites in Italy, the United States and Belgium moved to Novo Nordisk. As a result, capacity is consolidating around large originators, which can squeeze smaller sponsors.

How do cold chain demands raise distribution costs?

Cold chain demands raise distribution costs, because most biologics must stay refrigerated from the plant to the patient. Temperature excursions can ruin a full shipment, which forces distributors to use monitored packaging and faster delivery routes. This problem is most serious in rural areas and in low-income countries with weak power supply. In turn, access to biologics in these settings remains limited, even when prices fall.

Why does price pressure weigh on value growth?

Price pressure weighs on value growth, because payers and governments target high-cost biologics for negotiation and tenders. Biosimilar entry lowers prices for major antibodies once patents expire in Europe and the United States. Generic sterile products, such as older anesthetics and anti-infectives, also face thin margins that discourage new suppliers. As a result, value growth depends heavily on new brands rather than older volume products.

How do injection-site reactions and administration burden slow uptake?

Injection-site reactions and administration burden slow uptake, because some patients avoid needles or stop treatment after side effects. Roche reported that about 49% of trial participants had an injection reaction after the first subcutaneous Ocrevus dose, although all were mild or moderate. Clinic-given products also require nurse time, observation periods and premedication in many cases. For subcutaneous Ocrevus, patients are monitored for at least 60 minutes after the first dose and 15 minutes after later doses. In turn, makers must invest in patient support, which raises the cost of each launch.

North America leads as Asia Pacific gains pace

Why does North America hold the largest regional share?

North America held a 45.0% share of 2025 value and grows at 5.92% a year through 2035. The United States drives this position, because branded antibodies, incretin therapies and specialty biologics carry high list prices. Most new subcutaneous forms, including Keytruda Qlex and Opdivo Qvantig, launched first in this market. However, price negotiation and biosimilar entry are lowering net prices for several large brands.

How fast is Asia Pacific adding treated patients?

Asia Pacific held a 21.0% share of 2025 value and is the fastest-growing region at 7.62% a year. China, India and Southeast Asia are expanding public insurance coverage for cancer and diabetes medicines. Local producers of biosimilars and insulin supply affordable options, which expands access in price-sensitive markets. As a result, the region adds the largest number of new patients on injected therapy through 2035.

Download Free Sample

What shapes demand across Europe?

Europe held a 25.0% share of 2025 value and grows at 5.62% a year, the slowest pace of the five regions. Germany, France, the United Kingdom, Italy and Spain account for most spending through national formularies and hospital tenders. Biosimilar uptake is high across the region, which lowers the cost of antibody treatment for health systems. However, these price controls keep value growth below the global average.

Where is Latin America adding demand?

Latin America held a 5.0% share of 2025 value and grows at 6.82% a year through 2035. Brazil and Mexico lead regional spending, while public programs buy insulin, anti-infectives and selected biologics through national tenders.

What limits growth in the Middle East and Africa?

The Middle East and Africa held a 4.0% share of 2025 value and grows at 6.92% a year through 2035. Gulf states fund branded biologics, while much of Africa relies on donor programs and limited cold chain capacity.

Download Free Sample

Approvals, plant plans and deals since 2024

Delivery platforms and formulation science lead innovation

• Hyaluronidase co-formulation allows large antibody doses to be given under the skin in minutes, which frees infusion capacity.
• Long-acting depot formulations release medicine over months, which supports twice-yearly prevention and maintenance schedules.
• High-concentration biologic formulation reduces injection volume, which makes home self-injection practical for more antibodies.
• Prefilled pen and autoinjector platforms simplify dosing for patients, which supports the move from hospital to home care.
• Continuous aseptic manufacturing shortens production cycles and lowers contamination risk, which helps ease sterile supply limits.

Biologic originators compete on delivery and capacity

Competition is led by large biologic originators with deep antibody, peptide and specialty portfolios. This report profiles 13 companies, and at least four of them announced FDA approvals or new manufacturing plans in 2024 and 2025. Eli Lilly and Co., Amgen Inc., AbbVie Inc. and Johnson and Johnson Services Inc. compete in immunology, metabolic and specialty medicines, where delivery convenience shapes prescriber choice. Roche, Bristol Myers Squibb Co. and AstraZeneca Plc lead in oncology antibodies and have introduced subcutaneous options since 2024. Gilead Sciences Inc. and GlaxoSmithKline Plc compete in long-acting infectious disease products, while Biogen Inc. and Takeda Pharmaceutical Co. Ltd. serve neurology, rare disease and plasma-derived segments. Baxter International Inc. supplies sterile hospital injectables, and Medtronic Plc participates through drug delivery systems. As a result, competition increasingly centers on delivery format, sterile capacity and access programs.

Companies profiled and their roles in this market

Delivery convenience sets the pace of change to 2035

Credence Research's view is that delivery convenience and sterile capacity will set the pace of change through 2035, while chronic disease keeps volumes rising. The overall market grows at 6.31% a year, supported by antibodies in cancer and immunology and by peptide hormones in diabetes and obesity. Biosimilar entry and price negotiation restrain value growth for older brands in the United States and Europe. Companies that pair subcutaneous or long-acting formats with reliable fill-finish capacity will win the most patients.

How Credence Research sized parenteral medicine spending

The report uses 2025 as the base year and 2026 to 2035 as the forecast period. Market values come from the Credence Research model, which builds spending by therapeutic area, molecule type, distribution channel and region. Regional and segment splits are Credence Research estimates informed by FDA approval records, regulator decisions and company press releases. No primary interviews or surveys were used in preparing this edition of the report.

Parenteral medicine spending outlook to 2035

By 2035, the injectable drugs market is projected to reach USD 1,144.90 billion, with growth led by antibodies, peptide hormones and long-acting formulations. Monoclonal antibodies will remain the largest therapeutic area, while subcutaneous versions take share from infused forms. North America keeps the highest spending per patient, although biosimilars and price negotiation limit price growth. Online pharmacies will handle a larger share of chronic self-injected therapy over the decade. As a result, advantage will depend on delivery platforms, sterile capacity and access programs.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.